GLB - Ticker AI Digest

GLB 06:31

Glanbia plc

Glanbia launches share buyback

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

Glanbia plc, the Better Nutrition company, announced on February 25, 2026, the launch of a share buyback program valued up to €50 million. The program aims to reduce the companys share capital by repurchasing and canceling ordinary shares. It will run from February 25, 2026, to September 30, 2026, unless terminated earlier, and is part of a larger €100 million buyback initiative. J&E Davy (Davy) will act as the principal for share purchases, operating independently within pre-set parameters. The buyback will initially be conducted under the authority granted at the 2025 Annual General Meeting (AGM), allowing repurchase of up to 10% of issued share capital (13,865,688 shares post-previous buybacks). Continuation beyond April 29, 2026, is contingent on shareholder approval at the 2026 AGM. The program complies with Euronext Dublin Listing Rules, EU Market Abuse Regulations, and Central Bank of Ireland guidelines. Glanbia confirmed it holds no unpublished inside information. Contact details for key executives and Davy representatives were provided.

Go Back To AI Charts

GLB 06:01

Glanbia plc

Glanbia Full Year 2025 Results

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary of Glanbia Full Year 2025 Results**

Glanbia plc, the Better Nutrition company, reported robust financial results for the 2025 fiscal year, ending January 3, 2026. Key highlights include

**Revenue Growth**Revenue increased by 2.3% to $3.9 billion, driven by like-for-like (LFL) growth across all three segments: Performance Nutrition (PN), Health & Nutrition (H&N), and Dairy Nutrition (DN).

**EBITDA Decline**EBITDA decreased by 9.4% to $499.1 million, primarily due to record whey input costs affecting the PN segment.

**Adjusted EPS**Adjusted earnings per share (EPS) declined by 3.4% to 134.93 cents, while basic EPS increased by 19.7% to 73.16 cents.

**Segment Performance**

**Performance Nutrition**LFL revenue growth of 4.5%, with Optimum Nutrition achieving 6.4% growth. EBITDA margin declined to 13.0% due to high whey costs.

**Health & Nutrition**LFL revenue growth of 6.8%, with strong volume growth. EBITDA margin improved to 18.4%.

**Dairy Nutrition**LFL volume growth of 4.2%, with EBITDA of $149.5 million.

**Capital Allocation**

Recommended a final dividend of 25.67 €cent, bringing the total 2025 dividend to 42.87 €cent, a 10% increase.

Returned €197 million to shareholders via share buybacks and approved an additional €100 million buyback for 2026.

**Strategic Updates**

Sold non-core brands SlimFast and Body & Fit.

Acquired Sweetmix and Scicore to enhance global scale in H&N.

Continued a group-wide transformation program targeting $60 million in annual cost savings by 2027.

**2026 Outlook**

Expects adjusted EPS growth of 7% to 11% and operating cash conversion of 85%+.

Segmental performance is expected to align with medium-term targets.

CEO Hugh McGuire emphasized the Groups resilience despite macroeconomic challenges, highlighting strong cash flow, strategic acquisitions, and progress on cost-saving initiatives. Glanbia remains focused on its medium-term targets, positioning itself as a leader in better nutrition.

Go Back To AI Charts

GLB 06:31

Glanbia plc

Glanbia launches share buyback

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary**

Glanbia plc, the Better Nutrition company, announced on February 25, 2026, the launch of a share buyback program valued up to €50 million. The program aims to reduce the companys share capital by repurchasing and canceling ordinary shares. It will run from February 25, 2026, to September 30, 2026, unless terminated earlier, and is part of a larger €100 million buyback initiative. J&E Davy (Davy) will act as the principal for share purchases, operating independently within pre-set parameters. The buyback will initially be conducted under the authority granted at the 2025 Annual General Meeting (AGM), allowing repurchase of up to 10% of issued share capital (13,865,688 shares post-previous buybacks). Continuation beyond April 29, 2026, is contingent on shareholder approval at the 2026 AGM. The program complies with Euronext Dublin Listing Rules, EU Market Abuse Regulations, and Central Bank of Ireland guidelines. Glanbia confirmed it holds no unpublished inside information. Contact details for key executives and Davy representatives were provided.

Go Back To AI Charts

GLB 06:01

Glanbia plc

Glanbia Full Year 2025 Results

Open AI Digest

Go Back To AI Charts

Return to today’s catalyst cards, chart beacons and AI charts.

**Summary of Glanbia Full Year 2025 Results**

Glanbia plc, the Better Nutrition company, reported robust financial results for the 2025 fiscal year, ending January 3, 2026. Key highlights include

**Revenue Growth**Revenue increased by 2.3% to $3.9 billion, driven by like-for-like (LFL) growth across all three segments: Performance Nutrition (PN), Health & Nutrition (H&N), and Dairy Nutrition (DN).

**EBITDA Decline**EBITDA decreased by 9.4% to $499.1 million, primarily due to record whey input costs affecting the PN segment.

**Adjusted EPS**Adjusted earnings per share (EPS) declined by 3.4% to 134.93 cents, while basic EPS increased by 19.7% to 73.16 cents.

**Segment Performance**

**Performance Nutrition**LFL revenue growth of 4.5%, with Optimum Nutrition achieving 6.4% growth. EBITDA margin declined to 13.0% due to high whey costs.

**Health & Nutrition**LFL revenue growth of 6.8%, with strong volume growth. EBITDA margin improved to 18.4%.

**Dairy Nutrition**LFL volume growth of 4.2%, with EBITDA of $149.5 million.

**Capital Allocation**

Recommended a final dividend of 25.67 €cent, bringing the total 2025 dividend to 42.87 €cent, a 10% increase.

Returned €197 million to shareholders via share buybacks and approved an additional €100 million buyback for 2026.

**Strategic Updates**

Sold non-core brands SlimFast and Body & Fit.

Acquired Sweetmix and Scicore to enhance global scale in H&N.

Continued a group-wide transformation program targeting $60 million in annual cost savings by 2027.

**2026 Outlook**

Expects adjusted EPS growth of 7% to 11% and operating cash conversion of 85%+.

Segmental performance is expected to align with medium-term targets.

CEO Hugh McGuire emphasized the Groups resilience despite macroeconomic challenges, highlighting strong cash flow, strategic acquisitions, and progress on cost-saving initiatives. Glanbia remains focused on its medium-term targets, positioning itself as a leader in better nutrition.

Go Back To AI Charts